BALLkine 2
Alternative Names: BALLkine-2Latest Information Update: 26 Apr 2021
At a glance
- Originator Lemonex
- Class Antineoplastics; Cytokines; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Mar 2021 BALLkine 2 is available for licensing as of 31 Mar 2021. http://www.lemonexbio.com/kwa-2124980#sub4_1
- 19 Jan 2021 Preclinical trials in Solid tumours in South Korea (SC) before January 2021 (Lemonex pipeline, January 2021)